Literature DB >> 17019794

Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates.

Nirag Jhala1, Darshana Jhala, Selwyn M Vickers, Isam Eltoum, Surinder K Batra, Upender Manne, Mohamad Eloubeidi, Jennifer J Jones, William E Grizzle.   

Abstract

This study was undertaken to determine whether recently identified proteins could be translated to clinical practice as markers to distinguish pancreatic adenocarcinoma from chronic pancreatitis on fine-needle aspirate (FNA) samples. Resected pancreatic tissue sections (n = 40) and FNA samples (n = 65) were stained for clusterin-beta, MUC4, survivin, and mesothelin. For each biomarker, the staining patterns in adenocarcinoma and in reactive ductal epithelium were evaluated and compared. Clusterin-beta stained reactive ductal epithelium significantly more frequently than pancreatic adenocarcinoma (P < .001). In comparison, MUC4 and mesothelin were expressed more frequently in pancreatic adenocarcinoma on tissue sections. Positive staining for MUC4 (91% vs 0%; P < .001) and mesothelin (62% vs 0%; P = .01) and absence of staining for clusterin-beta (90% vs 7%; P < .001) were noted significantly more frequently in adenocarcinoma cells than in reactive cells in FNA samples. Clusterin-beta and MUC4 can help distinguish reactive ductal epithelial cells from the cells of pancreatic adenocarcinoma in FNA samples.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17019794     DOI: 10.1309/cev30be088cbdqd9

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  48 in total

1.  Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis.

Authors:  Qianqian Wang; Tao Wang; Zhu Wang; Hong Zheng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

Authors:  Hector Alvarez; Pamela Leal Rojas; Ken-Tye Yong; Hong Ding; Gaixia Xu; Paras N Prasad; Jean Wang; Marcia Canto; James R Eshleman; Elizabeth A Montgomery; Anirban Maitra
Journal:  Nanomedicine       Date:  2008-08-08       Impact factor: 5.307

Review 3.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

4.  Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering.

Authors:  Gufeng Wang; Robert J Lipert; Maneesh Jain; Sukhwinder Kaur; Subhankar Chakraboty; Maria P Torres; Surinder K Batra; Randall E Brand; Marc D Porter
Journal:  Anal Chem       Date:  2011-03-10       Impact factor: 6.986

5.  Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis.

Authors:  Lin Zhu; Yiling Liu; Guangyuan Chen
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 6.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

7.  Mesothelin expression in the leptomeninges and meningiomas.

Authors:  Mahlon D Johnson; Fran Vito; Mary J O'Connell
Journal:  J Histochem Cytochem       Date:  2008-03-17       Impact factor: 2.479

8.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

9.  Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Authors:  Shinji Mizuarai; Kazunori Yamanaka; Hiraku Itadani; Tsuyoshi Arai; Toshihide Nishibata; Hiroshi Hirai; Hidehito Kotani
Journal:  Mol Cancer       Date:  2009-06-08       Impact factor: 27.401

10.  External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas.

Authors:  Karolina Partheen; Kristina Levan; Lovisa Osterberg; Ingela Claesson; Karin Sundfeldt; György Horvath
Journal:  BMC Cancer       Date:  2009-09-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.